GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Inventories, Inventories Adjustments

Atossa Therapeutics (FRA:YAG2) Inventories, Inventories Adjustments : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Inventories, Inventories Adjustments?

Atossa Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2024 was €0.00 Mil.


Atossa Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Atossa Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Inventories, Inventories Adjustments Chart

Atossa Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atossa Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Atossa Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Atossa Therapeutics (FRA:YAG2) Business Description

Industry
Traded in Other Exchanges
Address
107 Spring Street, Seattle, WA, USA, 98104
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines